Pedro Eduardo Nascimento Silva Vasconcelos

Dr. Pedro Eduardo Nascimento Silva Vasconcelos

Brazilian Center for Research in Energy and Materials - CNPEM, Campinas, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in JTO Clinical and Research Reports
Verified
Journal Article
Open access
Pedro Eduardo Nascimento Silva VasconcelosPedro Eduardo Nascimento Silva Vasconcelos
Pedro Eduardo Nascimento Silva Vasconcelos
CGCarol Gergis
Carol Gergis
HVHollis Viray
Hollis Viray
AVAndreas Varkaris
Andreas Varkaris
MFMasanori Fujii
Masanori Fujii
DCDaniel Costa
Daniel Costa
The EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation (~5% to 6% of exon 20 insertions), which, at the structural and enzyme kinetic level, more closely resembles EGFR tyrosine kinase inhibitor (TKI)- sensitizing mutants, such as EGFR exon 19 indels and L858R. A limited number of preclinical models and clinical reports have studied the response of this mutant to EGFR TKIs. We used models of EGFR-A763_Y764insFQEA and more typical EGFR exon 20 insertion mutations to probe representative first- (gefitinib, erlotinib), second- (afatinib), third-generation (osimertinib), and in-development EGFR exon 20–specific (poziotinib, mobocertinib [TAK-788]) TKIs. We also compiled outcomes of EGFR-A763_Y764insFQEA-mutated lung cancers treated with EGFR TKIs. Cells driven by EGFR-A763_Y764insFQEA were consistently sensitive to EGFR TKIs (as opposed to those driven by typical EGFR exon 20 insertions [A767_V769dupASV, D770_N771insSVD and H773_V774insH]), which were only inhibited by in-development EGFR TKIs at doses below those affecting wild-type EGFR. Most case instances (62.5% [95% confidence interval: 39%–86%], n = 16) with lung cancers harboring EGFR-A763_Y764insFQEA responded to clinically available EGFR TKIs (including osimertinib) and to in-development EGFR exon 20-specific TKIs (including mobocertinib) with prolonged periods of progression-free survival in some cases. Median overall survival for EGFR TKI–treated cases was 22 months (95% confidence interval: 16–25). Mechanisms of acquired TKI resistance of this mutant remain underreported, but do seem to align with those of common mutations. To our knowledge, this is the largest report to confirm that the EGFR-A763_Y764insFQEA mutation is sensitive to clinically available first-, second-, third-generation, and in-development EGFR TKIs.

17 March 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ANAline de Souza Nicoletti
Aline de Souza Nicoletti
MVMarília Berlofa Visacri
Marília Berlofa Visacri
CRCarla Regina da Silva Correa da Ronda
Carla Regina da Silva Correa da Ronda
Pedro Eduardo Nascimento Silva VasconcelosPedro Eduardo Nascimento Silva Vasconcelos
Pedro Eduardo Nascimento Silva Vasconcelos
JQJulia Quintanilha
Julia Quintanilha
EPEder de Carvalho Pincinato
Eder de Carvalho Pincinato

21 January 2019 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
KMKaren P. H Mattos
Karen P. H Mattos
IGIsabela R. Gouvêa
Isabela R. Gouvêa
JQJúlia C. F. Quintanilha
Júlia C. F. Quintanilha
MCMaria A. Cursino
Maria A. Cursino
Pedro Eduardo Nascimento Silva VasconcelosPedro Eduardo Nascimento Silva Vasconcelos
Pedro Eduardo Nascimento Silva Vasconcelos
PMPatricia Moriel
Patricia Moriel

1 March 2021 in JTO Clinical and Research Reports
Verified
Journal Article
Open access
Pedro Eduardo Nascimento Silva VasconcelosPedro Eduardo Nascimento Silva Vasconcelos
Pedro Eduardo Nascimento Silva Vasconcelos
IKIkei S. Kobayashi
Ikei S. Kobayashi
SKSusumu S. Kobayashi
Susumu S. Kobayashi
DCDaniel Costa
Daniel Costa
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Novel EGFR-TKIs have been developed or repurposed for these mutants. A limited number of preclinical studies have detailed these EGFR-TKIs. We sought to use commercially available mobocertinib (TAK-788) to characterize the preclinical therapeutic window of this EGFR-TKI against EGFR mutations and to probe possible on-target mechanisms of resistance (EGFR-C797S). We used models of EGFR mutations to probe representative 1st, 2nd, 3rd generation, and in-development EGFR exon 20-active (poziotinib, mobocertinib) TKIs. We also introduced EGFR-C797S to these models to identify mechanisms of resistance. Cells driven by the most common EGFR exon 20 insertion mutations (A767_V769dupASV, D770_N771 insSVD, H773_V774insH and others) were inhibited by in-development EGFR TKIs at doses below those affecting EGFR-wildtype; albeit more common EGFR mutations (exon 19 deletions and L858R) were inhibited more readily by mobocertinib and poziotinib. Mobocertinib was able to inhibit phosphorylation of EGFR in multiple preclinical models. The presence of EGFR-C797S led to >200-fold resistance in proliferation assays probing mobocertinib and osimertinib. Review of clinical studies of mobocertinib disclosed responses that could be lasting. This is one of the initial reports to characterize the novel EGFR TKI mobocertinib and highlights its broad activity against EGFR mutants plus the therapeutic window to EGFR exon 20 insertion mutations; as well as EGFR-C797S as a possible mechanism of resistance. Further clinical development of mobocertinib merits continuation.

Verified
Journal Article
Open access
PDF file
NTNadine de Godoy Torso
Nadine de Godoy Torso
JPJoão Kleber Novais Pereira
João Kleber Novais Pereira
MVMarília Berlofa Visacri
Marília Berlofa Visacri
Pedro Eduardo Nascimento Silva VasconcelosPedro Eduardo Nascimento Silva Vasconcelos
Pedro Eduardo Nascimento Silva Vasconcelos
Pia Loren ReyesPia Loren Reyes
Pia Loren Reyes
PMPatricia Moriel
Patricia Moriel
The purpose of this systematic review was to map out and summarize scientific evidence on dysregulated microRNAs (miRNAs) that can be possible biomarkers or therapeutic targets for cisplatin nephrotoxicity and have already been tested in humans, animals, or cells. In addition, an in silico analysis of the two miRNAs found to be dysregulated in the majority of studies was performed. A literature search was performed using eight databases for studies published up to 4 July 2021. Two independent reviewers selected the studies and extracted the data; disagreements were resolved by a third and fourth reviewers. A total of 1002 records were identified, of which 30 met the eligibility criteria. All studies were published in English and reported between 2010 and 2021. The main findings were as follows: (a) miR-34a and miR-21 were the main miRNAs identified by the studies as possible biomarkers and therapeutic targets of cisplatin nephrotoxicity; (b) the in silico analysis revealed 124 and 131 different strongly validated targets for miR-34a and miR-21, respectively; and (c) studies in humans remain scarce.

5 July 2021 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Open access
PDF file
CVCamila O. Vaz
Camila O. Vaz
BMBruna M Mazetto
Bruna M Mazetto
Pedro Eduardo Nascimento Silva VasconcelosPedro Eduardo Nascimento Silva Vasconcelos
Pedro Eduardo Nascimento Silva Vasconcelos
LBLarissa B. Bastos
Larissa B. Bastos
MCMaria Aparecida Cursino
Maria Aparecida Cursino
FOFernanda A. Orsi
Fernanda A. Orsi
Antiphospholipid antibodies induce a pro-inflammatory and hypercoagulable state that lead to increased risk of thrombosis. Whether oxidative damage contributes thrombosis risk is a matter of debate. We evaluated the association between oxidative stress and thrombosis in primary antiphospholipid syndrome (t-PAPS). Plasma total antioxidant capacity and the levels of malondialdehyde (TBARs), carbonyl protein, and 8-isoprostane in plasma were determined in a group of patients with t-PAPS and in individuals without a history of thrombosis (controls) using commercial ELISA assays. The levels of these plasma markers of oxidative stress were compared between t-PAPS and controls using Mann–Whitney test. A total of 70 patients with t-PAPS and 74 controls were included. Overall, measurements of all plasma oxidative stress markers were similar between t-PAPS patients and controls. In a subgroup analysis, patients with t-PAPS and arterial thrombosis had a higher antioxidant capacity as compared to controls. Thrombotic PAPS was not associated with increased levels of oxidative stress markers, in comparison with individuals without thrombosis. Even though it is not possible to rule out that a mild oxidative damage, not detected by plasma markers, occurs in t-PAPS, our results suggest that measuring plasma oxidative stress markers has limited clinical relevance in t-PAPS.